- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT02340208
A Phase I/II Open-Label, Non-Randomized Dose Escalation Study of Immunoconjugate L-DOS47
A Phase I/II Open-Label, Non-Randomized Dose Escalation Study of Immunoconjugate L-DOS47 as a Monotherapy in Non-Squamous Non-Small Cell Lung Cancer Patients
Studieoversikt
Detaljert beskrivelse
Patients will be recruited into cohorts, with a minimum of three and a maximum of six patients per cohort. All patients at a given dose level must complete Cycle 1 (3 week period) before escalation in subsequent patients can proceed. The decision for dose escalation to the next dose level will be made after the safety and available pharmacokinetic (PK) data have been reviewed by the Trial Steering Committee (TSC).
Escalation of L-DOS47 will continue until a maximum tolerated dose (MTD) is reached.
After the MTD of L-DOS47 has been determined in Phase I, up to 20 patients will be enrolled (taken forward from Phase I) to evaluate the preliminary efficacy of L-DOS47 (i.e., response rate using the Response Evaluation Criteria in Solid Tumours [RECIST] version 1.1 criteria, disease progression and survival); monitoring will include radiologic evaluations every second cycle. The safety and tolerability of L-DOS47 will also be further evaluated. Pharmacokinetic information will be collected as well as relevant observations on the activity of L-DOS47.
For all patients, treatment with L-DOS47 will continue either until the patient experiences disease progression, unacceptable toxicity, the patient withdraws consent or has completed four treatment cycles and does not wish to continue with additional cycles, whichever occurs first. After four cycles, patients may continue to receive L-DOS47 for as long as there is sustained clinical benefit and it is well tolerated, in the opinion of the Investigator.
Studietype
Registrering (Faktiske)
Fase
- Fase 2
- Fase 1
Kontakter og plasseringer
Studiesteder
-
-
-
Otwock, Polen
- Mazovian Center of Pulmonary Diseases and Tuberculosis
-
Poznan, Polen
- Med. Polonia Hospital Poznan
-
Warsaw, Polen
- Institute of Tuberculosis and Lung Diseases
-
Warsaw, Polen
- Military Medical Institute
-
Warsaw, Polen
- The Maria Sklodowska-Curie Memorial Cancer Centre & Institute of Oncology
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Main Inclusion Criteria:
Patients will be entered in the study only if they meet all of the following criteria:
- Male or female aged ≥ 18 years old
Have histologically confirmed non-squamous NSCLC that are:
- Chemo naïve Stage IIIb or IV non-squamous NSCLC who are not candidates for chemotherapy or radiotherapy, or who refused standard therapy
- Refractory Stage IIIb or IV non-squamous NSCLC. (Staging of non-squamous NSCLC must be assessed according to TNM, 7th edition and based on computed tomography (CT) scan.)
- Have at least a single measurable lesion in accordance with the RECIST v1.1 criteria.
- Eastern Cooperative Oncology Group (ECOG) performance status: 0-2
- Have a life expectancy of ≥ 3 months
- Have adequate bone marrow, renal and liver function
Main Exclusion Criteria:
- Are pregnant or nursing mother
- Have a prior history of other malignancies with the exception of non melanoma skin cancer
- Have known history of central nervous system (CNS) metastatic disease (previously treated or untreated)
- Show evidence of active infection
- Have received treatment in another clinical study within the 30 days before commencing study drug or have not recovered from side effects of a study drug, except for alopecia
- Have a serious uncontrolled medical condition
- Known positive human immunodeficiency virus (HIV), known hepatitis B surface antigen, or hepatitis C positive
- Sustained QTc (QT interval corrected for heart rate) with Fridericia's correction > 450 ms at screening, or a history of additional risk factors for Torsades de pointes (e.g., heart failure, hypokalemia, family history of long QT syndrome)
- Pre-existing peripheral neuropathy ≥ CTC Grade 2
- Have dementia or significantly altered mental status that would prohibit the understanding or rendering of informed consent or compliance with the requirements of the protocol
- Are receiving chemotherapy during the 30 days before study treatment start; are receiving radiotherapy, targeted therapy, hormonal therapy, immunotherapy, major surgery or other study drugs during the 4 weeks before study treatment start, or have not recovered from all treatment related toxicities to Grade ≤ 1, except for alopecia. (Radiotherapy is allowed for the symptomatic treatment of bone metastases.)
- Are taking systemic steroids (other than inhalers or topical steroids) or other medication to suppress the immune system
- Are participating (or planning to participate) in any other clinical trial during this study.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: L-DOS47
Patient will be recruited into cohorts of L-DOS47 escalating doses, with a minimum of 3 and a maximum of 6 patients per cohort.
The starting dose of L-DOS47 will be 0.12 μg/kg; further possible dose levels include 0.21, 0.33, 0.46, 0.59, 0.78, 1.04, 1.38, 1.84, 2.45, 3.26 and 4.33 μg/kg.
|
A treatment cycle will be 21 days with patients receiving L-DOS47 on cycle Days 1 and 8.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
The incidence and severity of drug-related adverse events as a measure of safety and tolerability of L-DOS47
Tidsramme: Up to 12 weeks
|
Assessed during the AE reporting period starts on Cycle 1 Day 1 up to the last study visit.
|
Up to 12 weeks
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
L-DOS47 related toxicity during the first 2 hours after infusion
Tidsramme: During the first 2 hours after infusion
|
Assessed by the incidence and severity of AEs and SAEs and changes in vital signs
|
During the first 2 hours after infusion
|
The incidence and severity of all reported adverse events and serious adverse events
Tidsramme: Participants will be followed for 12 weeks and the 30 day follow-up period
|
Assessed during the AE reporting period starts on Cycle 1 Day 1 up to the last study visit.
|
Participants will be followed for 12 weeks and the 30 day follow-up period
|
Changes from baseline for additional safety parameters (clinical laboratory assessments, vital signs, weight, oxygen requirement and 12-lead ECG)
Tidsramme: Up to 12 weeks
|
Safety parameters include clinical laboratory assessments, vital signs, weight, oxygen requirement and 12-lead ECG
|
Up to 12 weeks
|
The evaluation of anti-L-DOS47 antibody over time
Tidsramme: Up to 12 weeks
|
Serum samples will be collected and analyzed from all patients dosed with L-DOS47.
|
Up to 12 weeks
|
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Maximum observed plasma concentration (Cmax) of L-DOS47 at each dose level
Tidsramme: Up to 12 weeks
|
Pharmacokinetic parameters for L-DOS47 will be determined from plasma samples collected from all patient dosed with L-DOS47.
|
Up to 12 weeks
|
Time to maximum observed plasma concentration (Tmax) of L-DOS47 at each dose level
Tidsramme: Up to 12 weeks
|
Pharmacokinetic parameters for L-DOS47 will be determined from plasma samples collected from all patient dosed with L-DOS47.
|
Up to 12 weeks
|
Area under the concentration (AUC) vs time curve of L-DOS47 at each dose level
Tidsramme: Up to 12 weeks
|
Pharmacokinetic parameters for L-DOS47 will be determined from plasma samples collected from all patient dosed with L-DOS47.
|
Up to 12 weeks
|
Terminal elimination half-life of L-DOS47 at each dose level
Tidsramme: Up to 12 weeks
|
Pharmacokinetic parameters for L-DOS47 will be determined from plasma samples collected from all patient dosed with L-DOS47.
|
Up to 12 weeks
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Dariusz Kowalski, MD, PhD, The Maria Sklodowska-Curie Memorial Cancer Centre & Institute of Oncology
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- LDOS002
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Ikke-småcellet lungekreft
-
AHS Cancer Control AlbertaCross Cancer InstituteFullførtOmfattende Stage Small Cel Lung CancerCanada
-
Memorial Sloan Kettering Cancer CenterAktiv, ikke rekrutterendeB-celle lymfom | B-celle non-hodgkin lymfom | B Cell ALLForente stater
-
University of WashingtonNational Cancer Institute (NCI); National Comprehensive Cancer NetworkAvsluttetTilbakevendende mantelcellelymfom | Refraktært mantelcellelymfom | Ann Arbor Stage I Mantelcellelymfom | Ann Arbor Stage II mantelcellelymfom | Ann Arbor Stage III Mantle Cell Lymfom | Ann Arbor Stage IV Mantle Cell LymfomForente stater
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.UkjentTilbakefallende / Refractory Mantle Cell Lymfom (MCL)Kina
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Aktiv, ikke rekrutterendeMantelcellelymfom | Blastoid Variant Mantle Cell Lymfom | Pleomorf variant av mantelcellelymfomForente stater
-
BeiGeneRekrutteringMantelcellelymfom | Residiverende mantelcellelymfom | Refractory Mantle Cell Lymfom (MCL)Forente stater, Kina, Israel, Belgia, Polen, Spania, Tyrkia, Brasil, Italia, Canada, Storbritannia, Frankrike, Tyskland, Argentina, Puerto Rico
-
City of Hope Medical CenterNational Cancer Institute (NCI)RekrutteringMantelcellelymfom | Blastoid Variant Mantle Cell Lymfom | Pleomorf variant av mantelcellelymfomForente stater
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Aktiv, ikke rekrutterendeAnn Arbor stadium I grad 1 follikulært lymfom | Ann Arbor stadium I grad 2 follikulært lymfom | Ann Arbor stadium II grad 1 follikulært lymfom | Ann Arbor stadium II grad 2 follikulært lymfom | Ann Arbor Stage IV B-celle non-Hodgkin lymfom | Ann Arbor Stage I B-celle non-Hodgkin lymfom | Ann Arbor... og andre forholdForente stater
-
Xiangyang No.1 People's HospitalQingdao Haier Biotechnology Co.,Ltd.Har ikke rekruttert ennåB-celle lymfom refraktært | B-celle lymfom Tilbakevendende | NK CellKina
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)FullførtAnn Arbor stadium III grad 1 follikulært lymfom | Ann Arbor stadium III grad 2 follikulært lymfom | Ann Arbor Stage III Indolent voksen non-Hodgkin lymfom | Ann Arbor Stage IV Grad 1 Follikulært lymfom | Ann Arbor Stage IV Grad 2 Follikulært lymfom | Ann Arbor Stage IV Indolent voksen non-Hodgkin... og andre forholdForente stater
Kliniske studier på L-DOS47
-
Helix BioPharma CorporationTheradexFullførtIkke-småcellet lungekreftForente stater
-
Helix BioPharma CorporationTheradexRekruttering
-
Helix BioPharma CorporationKCR S.A.AvsluttetLungeadenokarsinomPolen, Ukraina
-
Massachusetts General HospitalNeurocentria, Inc.FullførtADHD | Attention Deficit/Hyperactivity DisorderForente stater
-
Juliano CasonattoUkjent
-
Sidney Kimmel Cancer Center at Thomas Jefferson...United States Department of DefenseAktiv, ikke rekrutterendeKolorektalt adenom | Trinn III tykktarmskreft AJCC v8 | Trinn IIIA tykktarmskreft AJCC v8 | Trinn IIIB tykktarmskreft AJCC v8 | Stage IIIC tykktarmskreft AJCC v8 | Trinn 0 kolorektal kreft AJCC v8 | Fase I tykktarmskreft AJCC v8 | Trinn II kolorektal kreft AJCC v8 | Fase IIA tykktarmskreft AJCC v8 | Stage... og andre forholdForente stater
-
Zhongshan Hospital Xiamen UniversityRekrutteringHypotyreose | Kreft i skjoldbruskkjertelen, papillærKina
-
Marc-André Maheu-CadotteFullførtHjertefeil | MotivasjonCanada
-
Gdansk University of Physical Education and SportMedical University of GdanskFullført
-
University of OregonNational Institute on Aging (NIA); Oregon Health and Science University; University... og andre samarbeidspartnereUkjentLivskvalitet | MuskelatrofiForente stater